CalciMedica, Inc. Common Stock - Asset Resilience Ratio
CalciMedica, Inc. Common Stock (CALC) has an Asset Resilience Ratio of 11.01% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read CALC liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2025)
This chart shows how CalciMedica, Inc. Common Stock's Asset Resilience Ratio has changed over time. See CalciMedica, Inc. Common Stock book value and equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down CalciMedica, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see CalciMedica, Inc. Common Stock (CALC) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.50 Million | 11.01% |
| Total Liquid Assets | $1.50 Million | 11.01% |
Asset Resilience Insights
- Moderate Liquidity: CalciMedica, Inc. Common Stock has 11.01% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
CalciMedica, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare CalciMedica, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233 |
Biotechnology | 0.02% |
|
Staidson Beijing Biopharma
SHE:300204 |
Biotechnology | 7.93% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 41.25% |
|
Ardelyx Inc
NASDAQ:ARDX |
Biotechnology | 41.14% |
|
Xiangxue Pharmaceutical
SHE:300147 |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for CalciMedica, Inc. Common Stock (2019–2025)
The table below shows the annual Asset Resilience Ratio data for CalciMedica, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 11.01% | $1.50 Million | $13.59 Million | -43.22pp |
| 2024-12-31 | 54.23% | $10.73 Million | $19.79 Million | +7.38pp |
| 2023-12-31 | 46.84% | $5.71 Million | $12.19 Million | -25.97pp |
| 2021-12-31 | 72.81% | $50.31 Million | $69.09 Million | +12.29pp |
| 2020-12-31 | 60.53% | $61.62 Million | $101.79 Million | +11.13pp |
| 2019-12-31 | 49.40% | $20.09 Million | $40.66 Million | -- |
About CalciMedica, Inc. Common Stock
CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-… Read more